Functional Tricuspid Regurgitation (TR) Clinical Trial
Official title:
A First in Human Study to Assess Safety and Performance of the DaVingi™ System in the Treatment of Patients With Functional Tricuspid Regurgitation
| NCT number | NCT03700918 |
| Other study ID # | CLP-001 |
| Secondary ID | |
| Status | Recruiting |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | November 11, 2017 |
| Est. completion date | June 2022 |
The DaVingi™ System is a percutaneous trans-catheter device delivered using right heart catheterization through the right internal jugular vein. The DaVingi™ System is designed for performing ring annuloplasty by using a Ring Delivery System to place a complete, flexible fabric ring around the annulus of the atrial side of the tricuspid valve. Fluoroscopy and echocardiography are used to monitor the ring placement procedure.
| Status | Recruiting |
| Enrollment | 15 |
| Est. completion date | June 2022 |
| Est. primary completion date | December 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Severe tricuspid regurgitation as defined by American Society of Echocardiography. 2. Symptoms of right ventricular failure despite appropriate medical therapy. 3. Multidisciplinary heart team (minimum of three physicians, including cardiology and cardiac surgery representatives) recommends tricuspid annuloplasty. 4. =18 years old at time of enrollment. 5. LVEF = 30% within 45 days prior to index implant procedure. 6. PASP < 70 mmHg via right heart catheterization (subject at rest) within 90 days prior to index implant procedure. 7. Right Ventricle TAPSE = 13 mm within 45 days prior to index implant procedure. 8. Tricuspid valve annular diameter = 40 mm as measured by baseline transthoracic echocardiography in the 4 chamber view within 45 days prior to index implant procedure. 9. Subject has provided written informed consent. 10. Subject agrees to comply with all required post-procedure follow-up visits, including device adjustment. Exclusion Criteria: 1. Acutely decompensated heart failure (i.e. hemodynamically unstable or on IV inotropes). 2. Severe Right Ventricle dysfunction. 3. Primary tricuspid pathology (e.g. rheumatic, congenital, infective, etc.). 4. Previous tricuspid valve repair or replacement. 5. Transvalvular pacemaker or defibrillator lead is present. 6. Severe left-sided valve disease. 7. Right-sided intra-cardiac mass, thrombus or vegetation is present. 8. Inability to properly guide the index implant procedure using Trans-esophagus echocardiography (e.g. acoustic window not adequate). 9. Subject requires chronic dialysis or renal replacement therapy. 10. MI or known unstable angina within the 30-days prior to the implant index procedure. 11. CVA within 3 months prior to index implant procedure. 12. Bleeding disorders, active peptic ulcer or GI bleed. 13. Contraindication to anticoagulation or antiplatelet medication, based on investigator's opinion. 14. Chronic oral steroid or immunomodulator use (= 6 months) or other condition that could impair healing response (e.g. cardiac sarcoidosis or other chronic inflammatory disease). 15. Any condition that, in the opinion of the investigator, may render the subject unable to complete the study (life expectancy < 1 year), or lead to difficulties for subject compliance with study requirements. 16. Subject is enrolled in another investigational study which has not completed the required primary endpoint follow-up period (Note: patients involved in a long-term surveillance phase of another study are eligible for this study). 17. Female patients who are pregnant or lactating. |
| Country | Name | City | State |
|---|---|---|---|
| Czechia | Na Homolce Hospital | Prague | |
| France | Hopital Bichat | Paris | |
| France | Institut Mutualiste Montsouris | Paris | |
| France | Clinique Pasteur | Toulouse | |
| Israel | Rambam Health Care Campus | Haifa |
| Lead Sponsor | Collaborator |
|---|---|
| Cardiac Implants LLC |
Czechia, France, Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Safety- the incidence and severity of device-related serious adverse device effects (SADE) | the incidence and severity of device-related serious adverse device effects (SADE) from time of index implant/ adjustment procedure through 30 days post-implant | from time of index implant/ adjustment procedure through 30 days post-implant | |
| Primary | Device performance - Adjustment Device Technical Success: Rate of successful adjustment of the DaVingi™ TR ring at the tricuspid annulus, desired by physician | Implant Device Technical Success and Adjustment Device Technical Success | Immediately after procedure | |
| Secondary | safety - Incidence of device-related major adverse cardiac events (MACE) | Incidence of device-related major adverse cardiac events (MACE) | 30 days post procedure | |
| Secondary | safety - Rate of procedure-related serious adverse events (SAE) | Rate of procedure-related serious adverse events (SAE) | 30 days post procedure |